Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
13.49
+0.80 (6.30%)
At close: Oct 7, 2025, 4:00 PM EDT
13.59
+0.10 (0.74%)
After-hours: Oct 7, 2025, 5:43 PM EDT
Amylyx Pharmaceuticals Revenue
Amylyx Pharmaceuticals had revenue of $-249.00K in the twelve months ending June 30, 2025, down -100.08% year-over-year. In the year 2024, Amylyx Pharmaceuticals had annual revenue of $87.37M, down -77.06%.
Revenue (ttm)
$-249.00K
Revenue Growth
-100.08%
P/S Ratio
-5,778.89
Revenue / Employee
n/a
Employees
123
Market Cap
1.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 87.37M | -293.42M | -77.06% |
| Dec 31, 2023 | 380.79M | 358.56M | 1,612.94% |
| Dec 31, 2022 | 22.23M | 21.95M | 7,700.00% |
| Dec 31, 2021 | 285.00K | -365.00K | -56.15% |
| Dec 31, 2020 | 650.00K | -776.00K | -54.42% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AMLX News
- 27 days ago - Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock - Business Wire
- 4 weeks ago - Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire
- 4 weeks ago - Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 5 weeks ago - Amylyx to stop development of rare brain disorder drug after trial failure - Reuters
- 5 weeks ago - Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP) - Business Wire
- 6 weeks ago - Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript - Seeking Alpha